Fuyou Zhao1, Yuqing Chen2, Qiong Wu1, Zian Wang1, Jie Lu3. 1. Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College Bengbu, Anhui 233000, China. 2. Department of Respiratory Diseases, The First Affiliated Hospital of Bengbu Medical College Bengbu, Anhui 233000, China. 3. Department of Microbiology, Bengbu Medical College Bengbu, Anhui 233000, China.
Abstract
BACKGROUND: The prognostic value of CD117 expression in cancers has been evaluated for several years while the results remain controversial. We thus performed a systematic review and meta-analysis of studies assessing the impact of CD117 expression on overall survival (OS) and disease-free survival (DFS) to clarify this issue. METHODS: We searched Pubmed, Embase and Web of Science to identify studies on the prognostic impact of CD117 expression in cancers. A total of 4,458 patients from 39 eligible studies were included in the analysis. Pooled risk ratios (RRs) with 95% confidence interval (95% CI) were calculated to estimate the effect using random-effects model. RESULTS: The analysis indicated that CD117 had significant association with poor OS of osteosarcoma (OR=1.36, 95% CI=1.03-1.79, I2=0%, fixed model) and renal carcinoma (OR=4.86, 95% CI=2.72-8.67, I2=0%, fixed model).However, no significant association between CD117 and DFS was found in overall studies. CONCLUSIONS: CD117 expression might be a predictive factor of poor prognosis in some surgically treated cancers, particularly in renal carcinoma.
BACKGROUND: The prognostic value of CD117 expression in cancers has been evaluated for several years while the results remain controversial. We thus performed a systematic review and meta-analysis of studies assessing the impact of CD117 expression on overall survival (OS) and disease-free survival (DFS) to clarify this issue. METHODS: We searched Pubmed, Embase and Web of Science to identify studies on the prognostic impact of CD117 expression in cancers. A total of 4,458 patients from 39 eligible studies were included in the analysis. Pooled risk ratios (RRs) with 95% confidence interval (95% CI) were calculated to estimate the effect using random-effects model. RESULTS: The analysis indicated that CD117 had significant association with poor OS of osteosarcoma (OR=1.36, 95% CI=1.03-1.79, I2=0%, fixed model) and renal carcinoma (OR=4.86, 95% CI=2.72-8.67, I2=0%, fixed model).However, no significant association between CD117 and DFS was found in overall studies. CONCLUSIONS:CD117 expression might be a predictive factor of poor prognosis in some surgically treated cancers, particularly in renal carcinoma.
Authors: Carlos Camps; Rafael Sirera; Roy M Bremnes; Javier Garde; María José Safont; Ana Blasco; Alfonso Berrocal; José Javier Sánchez; Consuelo Calabuig; Miguel Martorell Journal: Lung Cancer Date: 2006-03-30 Impact factor: 5.705
Authors: E Kurt; C Sezgin; T Evrensel; U Yalcinkaya; O Kanat; A Veral; M Demiray; M Arslan; B Karabulut; I Ercan; E Goker; O Manavoglu Journal: Int J Clin Pract Date: 2005-05 Impact factor: 2.503
Authors: Leonardo Ferrari; Silvia Della Torre; Paola Collini; Antonia Martinetti; Giuseppe Procopio; Sara De Dosso; Roberto Bajetta; Laura Catena Journal: Tumori Date: 2006 Nov-Dec
Authors: Francesco Pepe; Pasquale Pisapia; Maria Laura Del Basso de Caro; Floriana Conticelli; Umberto Malapelle; Giancarlo Troncone; Juan Carlos Martinez Journal: Histol Histopathol Date: 2019-12-24 Impact factor: 2.303
Authors: Liang Zhou; Yu Zhang; Mark B Meads; Yun Dai; Yanxia Ning; Xiaoyan Hu; Lin Li; Kanika Sharma; Jewel Nkwocha; Rebecca Parker; Danny Bui; Jacquelyn McCarter; Lora Kramer; Cullen Purcell; Praneeth R Sudalagunta; Rafael R Canevarolo; Maria D Coelho Siqueira Silva; Gabriel De Avila; Raghunandan Reddy Alugubelli; Ariosto S Silva; Maciej Kmeiciak; Andrea Ferreira-Gonzalez; Kenneth H Shain; Steven Grant Journal: Blood Adv Date: 2021-10-12
Authors: C Alhan; T M Westers; E M P Cremers; C Cali; B I Witte; G J Ossenkoppele; A A van de Loosdrecht Journal: Leukemia Date: 2015-10-27 Impact factor: 11.528